The clinical course of multiple sclerosis patients in Hong Kong

Journal of the Neurological Sciences

Volumn 268, Issue 1-2, 2008, Pages 78-82

  Lau, Kwok kwong ^a   Wong, Winnie Wing Yin ^b   Sheng, Bun ^a   Yu, Ignatius Tak Sun ^c   Fung, Bun Hey ^d   Li, Ho Lun ^a   Ma, Ka Fai Johnny ^a   Wong, Lawrence Ka Sing ^e   Li, Patrick Chung Ki ^b  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Disease progression; Epidemiology; Extended Disability Status Scale; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; AGING; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SEX RATIO; WALKING AID;

ADULT; AGE FACTORS; AGE OF ONSET; DISABILITY EVALUATION; FEMALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREVALENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 40849115005     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.11.006     Document Type: Article

References (29)

1. Weinshenker B.G., and Ebers G.C. The natural history of multiple sclerosis. Can J Neurol Sci 14 (1987) 255-261
2. The IFNB multiple sclerosis study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: 1. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 43 (1993) 655-661
3. Paty D.W., and Li D.K.B. IFNB multiple sclerosis study group. Interferon beta-1b is effective in remitting-relapsing multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI study group. Neurology 43 (1993) 662-667
4. Saida T., Tashiro K., Itoyama T., et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64 (2005) 621-630
5. PRISMS Study group. Randomized double-blind placebo-controlled study of interferon β1a in relapsing-remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
6. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Ann Neurol 13 (1983) 227-231
7. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
8. Wasay M., Khatri I.A., Khealani B., and Sheerani M. MS in Asian countries. Mult Scler 13 (2006) 58-65
9. Yu Y.L., Woo E., Hawkins B.R., Ho H.C., and Huang C.Y. Multiple sclerosis amongst Chinese in Hong Kong. Brain 112 (1989) 1445-1467
10. Lau K.K., Wong L.K.S., Li L.S., Chan Y.W., Li H.L., and Wong V. Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J 8 (2002) 77-80
11. . (viewed on 25/01/2007).
12. Census and Statistics Department. Table 9 Population by Nationality, 1991, 1996 and 2001'. Population census 2001 (2001) summary results
13. Confavreux C., Vukusic S., Moreau T., and Adeleine P. Relapses and progression of disability in multiple sclerosis. N Eng J Med 343 (2000) 1430-1438
14. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 112 (1989) 133-146
15. Tremlett H., Paty D., and Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 66 (2006) 172-177
16. Kurtzke J.F., Beebe G.W., Nagler B., et al. Studies on the natural history of multiple sclerosis VIII. Early prognostic features of the later course of the illness. J Chron Dis 30 (1977) 819-830
17. Sadovnick A.D., and Ebers G.C. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 20 (1993) 17-29
18. Confavreux C., Vukusic S., and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesia process. Brian 126 (2003) 770-782
19. Vukusic S., and Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 20 (2007) 269-274
20. Kira J., Kanai T., Nishimura Y., et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 40 (1996) 569-574
21. Kappos L., Freedman M.S., Polman C.H., et al. Effects of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow up analysis of the BENEFIT study. Lancet 370 (2007) 389-397
22. Herndon R.M., and Rudick R.A. Multiple sclerosis: the spectrum of severity. Arch Neurol 40 (1983) 531-532
23. Gilbert J.J., and Sadler M. Unsuspected multiple sclerosis. Arch Neurol 40 (1983) 533-536
24. Weinshenker B.G., Rice G.P.A., Noseworthy J.H., et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 114 (1991) 1045-1056
25. Poser S., Raun N.E., and Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol Scand 66 (1982) 355-362
26. McAlpine D. The benign form of multiple sclerosis. Results of a long-term study. BMJ 2 (1964) 1029-1032
27. Runmarker B., and Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow-up. Brain 116 (1993) 117-134
28. McAlpine D., and Compston N. Some aspects of the natural history of disseminated sclerosis. Quart J Med 21 (1952) 135-167
29. Hawkins S.A., and McDonnell G.V. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67 (1999) 148-152